Keywords
multidrug-resistant pulmonary tuberculosis
fibrosis
oxyproline
aldosterone
metalloproteinase-9
tissue inhibitors of metalloproteinase-1
How to Cite
Abstract
It was examined 126 patients with firstly diagnosed pulmonary tuberculosis (FDTB) who were divided into groups depending on the sensitivity of the pathogen to antituberculosis drugs: multidrug-resistant tuberculosis group (MDR-TB group) and susceptible tuberculosis group (FDTB group). Patients were examined the levels of total oxyproline, free and protein-bounded oxyproline, as well as aldosterone, matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1) at the beginning of treatment, 2 and 3 months after the start of treatment. At the beginning of treatment, the significant difference in the groups was between the values of free oxyproline (was highest in MDR-TB group) and aldosterone (was highest in FDTB group). After 2 months of treatment the level of protein-bound oxyproline was significantly higher in the MDR-TB group, and the MMP-9 level was higher in the FDTB group. After 3 months the aldosterone level was significantly higher in the MDR-TB group, and the TIMP-1 level was significantly higher in the FDTB group. Also, in the FDTB group, a larger number of patients had sputum conversion after 2 months of treatment. In the MDRTB group, more intense destructive changes and a more protracted onset of reparative processes in the lung tissue were noted.References
Feshchenko Yu.I., Melnyk V.M., Turchenko L.V. (2015). Kontseptualni zasady optymizatsyi protytuberkulouznykh zakhodiv i reformuvannia protytuberkuloznoi sluzhby Ukrainy. Available at: ftp://ftp1.ifp.kiev.ua/original/2015/feschenko2015.pdf
Golomedova A.V., Galygina N.E., Stahanov V.A., Dan’kevich E.N. (2008). Sovershenstvovanie patogenetichheskoy terapii vpervye vyyavlennyh bol’nyh infil’trativnym tuberkulezom legkih. Vestnik RUDN. Ser.: Medicina, 7, 209–213.
Tarasova L.G., Strel’cova E.N., Kantemirova B.I. (2015). Immunogeneticheskie predposylki narusheniya metabolizma kollagena pri tuberkuleze. Tuberkulez i bolezni legkih, 11, 4–9.
Brew K., Nagase H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research, 1803 (1), 55–71. doi: 10.1016/j.bbamcr.2010.01.003
Bellayr I., Mu X., Li Y. (2009). Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments. Future Medicinal Chemistry, 1 (6), 1095–1111. doi: 10.4155/fmc.09.83
Elkington P.T., Ugarte-Gil C.A., Friedland J.S. (2011). Matrix metalloproteinases in tuberculosis. European Respiratory Journal, 38 (2), 456–464. doi: 10.1183/09031936.00015411
El Margoushy N.M., Khaleel A.T. (2013). Metaloproteinase and tissue inhibitor of metalloproteinase in tuberculosis and malignant pleural effusion. Egyptian J. of Chest Diseases and Tuberculosis, 62 (2), 235–240. doi: 10.1016/
j.ejcdt.2013.03.008
Kulish M.V. (2013). Vplyv kortykosteroidiv na funktsiiu kory nadnyrnykiv u khvorykh na vpershe diahnostovanyi destruktyvnyi tuberkuloz lehen. Problemy ekolohiy ta medytsyny, 17 (3–4), 21–26.
Nakaz MOZ Ukrainy vid 04.09.2014 № 620 «Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry tuberkulozi». Ministerstvo okhorony zdorovia Ukrainy. (2014). Kyiv. 179 p.
Sharaev P.N. (1981). Metod opredeleniya svobodnogo i svyazannogo oksiprolina v syvorotke krovi. Lab. delo, 5, 283–285.